TABLE 1.
Baseline clinical characteristics of patient cohort
| Characteristic | All patients | Patients who died |
|---|---|---|
| Gender | ||
| Female | 106 (46) | 13 (57) |
| Male | 124 (54) | 10 (43) |
| Age (median) (years) | 42 (1‐75) | 54 (32‐68) |
| <60 | 199 (86) | |
| ≥60 | 31 (14) | 5 (22) |
| Age (years) | ||
| ≤12 | 31 (14) | 0 |
| >12 | 199 (86) | 23 (100) |
| Smoking | ||
| Current smokers | 22 (10) | 0 |
| Never smokers | 196 (85) | 21 (91) |
| Status not known | 12 (5) | 2 (9) |
| Comorbidities | ||
| Diabetes mellitus | 30 (13) | 5 (22) |
| Hypertension | 25 (11) | 13 |
| Cardiac illness | 2 (1) | 0 |
| Primary cancer site | ||
| Hematolymphoid | 90 (38) | 8 (35) |
| Lymphoma | 31 (13) | 5 (22) |
| Leukemia | 47 (20) | 2 (9) |
| Other hematological | 12 (5) | 1 (4) |
| Solid tumor malignancies | 140 (62) | 15 (65) |
| Gastrointestinal | 39 (17) | 4 (17) |
| Breast | 30 (13) | 3 (13) |
| Sarcomas | 16 (8) | 1 (4) |
| Head and neck | 17 (7) | 3 (13) |
| Thoracic | 12 (5) | 2 (9) |
| Gynecological | 13 (6) | 2 (9) |
| Urological | 0 | |
| Central nervous system | 7 (3) | 0 |
| Cancer stage | ||
| Advanced/Metastatic solid malignancies | 52 (22) | 9 (39) |
| Stage I‐III (Localized/loco‐regionally advanced) solid malignancies | 93 (41) | 9 (39) |
| Hematolymphoid malignancies | 85 (37) | 5 (22) |
| Broad treatment intent | ||
| Curative | 171 (75) | 9 (39) |
| Palliative | 59 (25) | 14 (61) |
| Cancer status | ||
| Controlled cancer | 122 (53) | 5 (22) |
| Uncontrolled cancer | 32 (14) | 12 (52) |
| No response assessment (On treatment) | 76 (33) | 6 (26) |
| Severity of COVID‐19 | ||
| Mild | 195 (85) | 5 (22) |
| Moderate | 11 (5) | 1 (4) |
| Severe | 24 (11) | 17 (74) |
| Intensive care admission | 8 | 5 (22) |
Data are median or n (%).